Amgen (NQ: AMGN )
252.43 USD -0.19 (-0.08%) Streaming Delayed Price Updated: 3:51 PM EDT, May 11, 2021 Add to My Watchlist
Press releases about Amgen
Thinking about trading options or stock in Nio, Microsoft, Callaway Golf, Amgen, or Wayfair?
Today 9:31 EDT
Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21
Today 9:00 EDT
Final Analysis From Open-Label Extension Study in Patients with Human Immunodeficiency Virus and Dyslipidemia
deCODE genetics - Rounding off the human genome
May 10, 2021
In a study published today, scientists at deCODE Genetics demonstrate for the first time how long-read DNA sequencing can be applied at population scale to unravel large structural variants that...
Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, May 11, 2021. David M. Reese, M.D., executive vice president of...
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
May 05, 2021
Tags Featured News
Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized...
Amgen Reports First Quarter 2021 Financial Results
April 27, 2021
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2021. Key results include:
OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis
April 23, 2021
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the U.S. financial markets. The announcement will be followed...
Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
April 19, 2021
Potential First-in-Class Therapy for a Subset of Gastric and Gastroesophageal Cancers That Overexpress Fibroblast Growth Factor Receptor 2 (FGFR2b)
Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
April 19, 2021
Half of All Patients With NSCLC Have Oncogene Mutations, Yet Many Patients Are Not Tested to Screen for Biomarkers
Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX),...
Amgen to Acquire Rodeo Therapeutics Corporation
March 30, 2021
Preclinical Program Targeting 15-PGDH has Potential use in a Broad Range of Therapeutic Applications Including Inflammatory Disease Indications
NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) Developing Groundbreaking Anti-Inflammatory Therapeutics
March 26, 2021
Controlling Inflammation to Stop Disease
March 24, 2021
Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m. ET on Tuesday, March 16, 2021. David M. Reese, M.D., executive vice president of Research and...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Five Prime Therapeutics, Inc. ("Five Prime" or the "Company") (NASDAQ: FPRX)...
FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm
March 04, 2021
Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide
Amgen Announces 2021 Second Quarter Dividend
March 03, 2021
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will be paid on June 8, 2021, to all stockholders of...
BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
March 02, 2021
Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
February 26, 2021
Data From Investigational Therapy Tezepelumab Phase 3 NAVIGATOR Trial in Patients With Severe Asthma Presented at the American Academy of Asthma Allergy & Immunology Annual Meeting
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
February 25, 2021
Moderna reports fourth quarter and fiscal year 2020 financial results and provides business updates.
Amgen To Present At The Cowen 41st Annual Healthcare Conference
February 24, 2021
Amgen (NASDAQ:AMGN) will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021. Murdo Gordon, executive vice president of Global Commercial...
Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting
February 22, 2021
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting on Friday, Feb. 26, at...